Eli Lilly Förvaltning

Förvaltning kriterier kontrolleras 2/4

Eli Lilly VD är Dave Ricks, utsedd i Jan 2017, har en mandatperiod på 9.33 år. totala årliga ersättningen är $ 36.70M, bestående av 4.6% lön 95.4% bonusar, inklusive företagsaktier och optioner. äger direkt 0.091% av företagets aktier, värda ARS 1,154.77B. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 6.7 år respektive 9.9 år.

Viktig information

Dave Ricks

Verkställande direktör

US$36.7m

Total ersättning

VD-lön i procent	4.63%
Anställning som VD	9.3yrs
Ägande av VD	0.09%
Ledningens genomsnittliga anställningstid	6.7yrs
Styrelsens genomsnittliga mandatperiod	9.9yrs

Senaste uppdateringar av ledningen

Recent updates

Analys av ersättningar till VD

Hur har Dave Ricks:s ersättning förändrats jämfört med Eli Lilly:s resultat?
Datum	Total ersättning	Lön	Företagets resultat
Mar 31 2026	n/a	n/a	US$25b
Dec 31 2025	US$37m	US$2m	US$21b
Sep 30 2025	n/a	n/a	US$18b
Jun 30 2025	n/a	n/a	US$14b
Mar 31 2025	n/a	n/a	US$11b
Dec 31 2024	US$29m	US$2m	US$11b
Sep 30 2024	n/a	n/a	US$8b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b

Ersättning vs marknad: Dave s total kompensation ($USD 36.70M ) är över genomsnittet för företag av liknande storlek på AR marknaden ($USD 5.03M ).

Ersättning vs inkomst: Ersättningen för Dave har ökat med mer än 20 % det senaste året.

VD OCH KONCERNCHEF

Dave Ricks (57 yo)

9.3yrs

Anställning

US$36,698,337

Kompensation

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
David Ricks	Chairman & CEO	9.3yrs	US$36.70m	0.091% ARS 1.2t
Lucas Montarce	Executive VP & CFO	1.7yrs	US$8.48m	0.0018% ARS 23.0b
Daniel Skovronsky	Chief Scientific & Product Officer and President of Lilly Research Laboratories	7.9yrs	US$17.79m	0.026% ARS 333.7b
Anat Hakim	Executive VP	6.3yrs	US$9.85m	0.0062% ARS 78.7b
Jacob Van Naarden	Executive VP	no data	US$7.59m	0.0041% ARS 51.4b
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	13.5yrs	inga uppgifter	0.00059% ARS 7.5b
Diogo Rau	Executive VP and Chief Information & Digital Officer	5yrs	US$5.10m	0.0030% ARS 37.4b
Michael Czapar	Director of Investor Relations	7.5yrs	inga uppgifter	inga uppgifter
Eric Dozier	Executive VP & Chief People Officer	3.4yrs	inga uppgifter	0.0017% ARS 21.0b
Ilya Yuffa	Executive VP and President of Lilly USA & Global Customer Capabilities	5.6yrs	inga uppgifter	0.0036% ARS 45.7b
Patrik Jonsson	Executive VP & President of Lilly International	6.7yrs	US$3.92m	0.0069% ARS 86.7b
Frank Cunningham	Senior Vice President of Global Value & Access	6.8yrs	inga uppgifter	inga uppgifter

6.7yrs

Genomsnittlig anställningstid

51yo

Genomsnittlig ålder

Erfaren ledning: LLY s ledningsgrupp är erfaren och erfaren ( 6.7 års genomsnittlig anställning).

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
David Ricks	Chairman & CEO	9.3yrs	US$36.70m	0.091% ARS 1.2t
Gabrielle Sulzberger	Independent Director	5.3yrs	US$365.50k	0.00033% ARS 4.2b
Sidney Taurel	Chairman Emeritus	17.3yrs	US$13.06m	inga uppgifter
Jon Erik Fyrwald	Independent Director	20.5yrs	US$343.80k	0.00019% ARS 2.4b
Ralph Alvarez	Independent Director	17.1yrs	US$361.00k	0.000090% ARS 1.1b
Carolyn Bertozzi	Independent Director	less than a year	US$7.68k	0.00022% ARS 2.8b
William Kaelin	Independent Director	13.9yrs	US$392.00k	inga uppgifter
Mary Hedley	Independent Director	4yrs	US$339.00k	0.000040% ARS 505.1m
Juan Luciano	Lead Independent Director	10.3yrs	US$398.00k	0.0019% ARS 23.9b
Katherine Baicker	Independent Director	14.4yrs	US$361.00k	inga uppgifter
Jamere Jackson	Independent Director	9.6yrs	US$368.00k	0.000020% ARS 252.5m
Kimberly Johnson	Independent Director	5.3yrs	US$336.00k	inga uppgifter

9.9yrs

Genomsnittlig anställningstid

63.5yo

Genomsnittlig ålder

Erfaren styrelse: LLY s styrelse anses vara erfaren ( 9.9 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/21 21:14
Aktiekurs vid dagens slut	2026/05/21 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Eli Lilly and Company bevakas av 53 analytiker. 28 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
David Toung	Argus Research Company
Emily Field	Barclays
Kerry Holford	Berenberg

Eli Lilly Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Senaste uppdateringar av ledningen

Eli Lilly and Company, Annual General Meeting, May 04, 2026

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery

Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025

Eli Lilly and Company, Lilly Cardiometabolic Health and Lilly Usa, Llc Announces Executive Appointments

Recent updates

Walden Macht Haran & Williams LLP Secures Victory Against Eli Lilly and Company

Eli Lilly and Company Presents Results for Foundayo and Zepbound in Weight Loss Maintenance Trials

Eli Lilly and Company Announces Omvoh Demonstrates Durable Disease Clearance in Ulcerative Colitis Through Four Years

Eli Lilly and Company Raises Earning Guidance for the Year 2026

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire remaining majority stake in Ajax Therapeutics, Inc. for $2.3 billion.

Lilly Reportedly in Advanced Talks to Acquire Kelonia Therapeutics for over $2 Billion

Eli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular Risk

Eli Lilly And Company Announces Positive Phase 3 Results For Jaypirca (Pirtobrutinib) In Previously Treated CLL/SLL

Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S

Eli Lilly And Company Receives FDA Approval For Foundayo (Orforglipron) For Weight Loss

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders for $5.6 billion.

Eli Lilly and Company Presents Phase 3B Data on Taltz and Zepbound Combination for Adults with Psoriatic Arthritis and Obesity

Eli Lilly And Company Delivers Durable Disease Control With Ebglyss For Moderate-To-Severe Atopic Dermatitis

Eli Lilly And Company Demonstrates Significant Reductions In A1C And Weight With Retatrutide In First Phase 3 Trial For Treatment Of Type 2 Diabetes

Eli Lilly And Company Announces Positive Phase 3 Results For EBGLYSS In Pediatric Patients With Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Company, Annual General Meeting, May 04, 2026

Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding Actos

Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage Options

Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia Areata

Eli Lilly and Company Announces Detailed Results from ACHIEVE-3

Eli Lilly and Company Announces the U.S. Food and Drug Administration Approves a Label Expansion for Zepbound® (tirzepatide)

Eli Lilly and Company Presents New Long-Term Data from Eli Lilly and Company's Omvoh (mirikizumab-mrkz)

Eli Lilly and Company Announces Positive Topline Results from Taltz (Ixekizumab) and Zepbound (Tirzepatide)

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of Retevmo

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Orna Therapeutics, Inc. in a transaction valued at $2.4 billion.

Eli Lilly and Company Provides Earnings Guidance for the Full Year 2026

Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026

Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian Cancer

Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk

Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.

Ventyx Biosciences Reportedly in $1 Billion Acquisition Talks with Eli Lilly

Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).

Eli Lilly and Company Announces Oral GLP-1 Orforglipron

Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trial

Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical Trial

Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual Meeting

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of Eloralintide

Eli Lilly and Company Raises Earnings Guidance for the Year 2025

Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative Colitis

Eli Lilly and Company's Omvoh Demonstrates Early and Sustainable Improvement in Bowel Intention Outcomes for Patients with Ulcerative Colitis

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.

Eli Lilly and Company Announces Results from the Primary Overall Survival Analysis of the Phase 3 Monarche Trial

Eli Lilly and Company to Report Q3, 2025 Results on Oct 30, 2025

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 Trials

Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery

Eli Lilly and Company's Omvoh (mirikizumab-mrkz) Is the First and Only Interleukin-23p19 (IL-23p19) to Help Patients with Moderately Active Ulcerative Colitis Achieve Sured, Long-Term Outcomes Through Four Years

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Inluriyo (imlunestrant) for Adults with ER+, HER2, ESR1-Mutated Advanced or Metastatic Breast Cancer

Eli Lilly and Company Announces Detailed Results from Surpass-PEDS, the First Phase 3 Trial to Evaluate the Safety and Efficacy of Mounjaro

Eli Lilly and Company Announces Positive Topline Results from ACHIEVE-3

Eli Lilly and Company Launches TuneLab Platform to Give Biotechnology Companies Access to AI-Enabled Drug Discovery Models Built Through over $1 Billion in Research Investment

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-313 Clinical Trial of Jaypirca

Eli Lilly and Company Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed KRAS G12C-Mutant Lung Cancer

Eli Lilly and Company Announces Positive Topline Results from the Primary Overall Survival (OS) Analysis of the Phase 3 MonarchE Trial

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 Attain-2 Trial

Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025

Ken Paxton Files Lawsuit in State Court Against Eli Lilly and Co

Eli Lilly and Company Raises Earning Guidance for the Year 2025

Eli Lilly and Company Announces Topline Results from SURPASS-CVOT

Eli Lilly and Company Announces Results from the Long-Term Extension (LTE) of the Phase 3 Trailblazer-Alz 2 Study

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-314 Clinical Trial of Jaypirca

Eli Lilly and Company Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) in Early Symptomatic Alzheimer's Disease

Eli Lilly and Company to Report Q2, 2025 Results on Aug 07, 2025